Jason Morris

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Peter Chen, Ajay Nirula, Barry N. Heller et al. · New England Journal of Medicine · 2020 · 1.4K citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

Robert Gottlieb, Ajay Nirula, Peter Chen et al. · JAMA · 2021 · 947 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +15

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

Myron S. Cohen, Ajay Nirula, Mark J. Mulligan et al. · JAMA · 2021 · 208 citations · Full text

Medicine, Infectious Diseases, Preventive Medicine +10

Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19

Michael Dougan, Masoud Azizad, Peter Chen et al. · medRxiv · 2022 · 75 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load

Michael Dougan, Masoud Azizad, Bharat Mocherla et al. · Clinical Infectious Diseases · 2021 · 68 citations · Full text

Pharmacy, Internal Medicine, Pharmacotherapy +15